Home - Products - MAPK/ERK Signaling - p38 MAPK - methyl 5-(3,4-dimethoxyphenyl)isoxazole-3-carboxylate

methyl 5-(3,4-dimethoxyphenyl)isoxazole-3-carboxylate

CAS No. 517870-17-6

methyl 5-(3,4-dimethoxyphenyl)isoxazole-3-carboxylate( —— )

Catalog No. M24490 CAS No. 517870-17-6

methyl 5-(3,4-dimethoxyphenyl)isoxazole-3-carboxylate targets MAPK.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 45 In Stock
10MG 68 In Stock
25MG 115 In Stock
50MG 173 In Stock
100MG 258 In Stock
200MG 388 In Stock
500MG 642 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    methyl 5-(3,4-dimethoxyphenyl)isoxazole-3-carboxylate
  • Note
    Research use only, not for human use.
  • Brief Description
    methyl 5-(3,4-dimethoxyphenyl)isoxazole-3-carboxylate targets MAPK.
  • Description
    methyl 5-(3,4-dimethoxyphenyl)isoxazole-3-carboxylate targets MAPK.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    MAPK/ERK Signaling
  • Target
    p38 MAPK
  • Recptor
    MAPK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    517870-17-6
  • Formula Weight
    263.25
  • Molecular Formula
    C13H13NO5
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:10 mM
  • SMILES
    COC1=C(C=C(C=C1)C2=CC(=NO2)C(=O)OC)OC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • HPK1-IN-7

    HPK1-IN-7 is an orally active HPK1 inhibitor. It shows selectivity against IRAK4 (59 nM) and GLK (140 nM).

  • BMS-751324

    BMS-751324 is a novel clinical prodrug of BMS-582949, which is a highly selective p38α MAPK inhibitor with IC50 of 13 nM.

  • p38α inhibitor 1

    p38α inhibitor 1 is an inhibitor of p38α .